1-(2-氯-4-硝基-苯基)-哌啶 | 55403-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-氯-4-硝基-苯基)-哌啶
• 中文别名: 1-(2-氯-4-硝基苯基)哌啶
• 英文名称: 3-chloro-4-piperidinonitrobenzene
• 英文别名: 2-Chlor-1-piperidino-4-nitrobenzol；3-Chlor-4-piperidinonitrobenzol；1-(2-Chloro-4-nitro-phenyl)-piperidine；2-chloro-1-piperidino-4-nitrobenzene；1-(2-Chlor-4-nitro-phenyl)-piperidin；1-(2-Chloro-4-nitrophenyl)piperidine
• CAS: 55403-25-3
• 化学式: C₁₁H₁₃ClN₂O₂
• mdl: MFCD00218199
• 分子量: 240.689
• InChiKey: AIZKHORWEJERNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-氯-4-硝基-苯基)-哌啶 以98%的产率得到
  参考文献：
  名称：

  SPENCER C. F.; SNYDER JR. H. R.; BURCH H. A.; HATTON C. J., J. MED. CHEM. , 1977, 20, NO 6, 829-833

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基哌啶 、 3,4-二氯硝基苯 以 四氢呋喃 为溶剂， 80.0 ℃ 、750.0 MPa 条件下， 反应 20.0h， 以12.3%的产率得到1-(2-氯-4-硝基-苯基)-哌啶
  参考文献：
  名称：

  高压下单氯硝基苯、二氯硝基苯和三氯硝基苯与 N-甲基取代的环状叔胺的反应

  摘要：

  单-、二-和三氯硝基苯与 1-甲基吡咯烷在高压下反应，通过 SNAr 反应形成的季吡咯烷氯化物中间体产生去甲基化和开环产物。另一方面，与 1-甲基哌啶和 4-甲基吗啉的反应仅产生去甲基化产物。发现 1-甲基吡咯烷与这些氯硝基苯反应的选择性受吡咯烷鎓基团的相邻取代基的影响。

  DOI：

  10.1246/bcsj.68.2717

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines
  申请人：Morton-Norwich Products, Inc.

  公开号：US03947434A1

  公开（公告）日：1976-03-30

  A series of 9-(substituted amino)imidazo[4,5-f]quinolines are effective anthelmintic agents; particularly in respect to the tapeworm Hymenolepis nana.

  一系列9-(取代氨基)咪唑并[4,5-f]喹啉是有效的驱虫药物；特别对于绦虫Hymenolepis nana。
• Utilization of caffeine carbon supported cobalt catalyst in the tandem synthesis of pyrroles from nitroarenes and alkenyl diols
  作者：Dibyajyoti Panja、Anirban Sau、Bhuvaneshwari Balasubramaniam、Partha Dhara、Raju K. Gupta、Sabuj Kundu

  DOI：10.1016/j.jcat.2021.08.020

  日期：2021.10

  cobalt catalyst, synthesis of various substituted pyrrole derivatives is reported. In this methodology, pyrroles were synthesized through coupling between nitroarenes and alkenyl diols in a tandem manner. Among all the heterogeneous catalysts Co(OAc)2-CC-800 displayed the highest catalytic activity. Preparative scale synthesis of pyrroles and synthesis of anti-tubercular agent 5-(4-(1H-pyrrol-1-yl)phenyl)-1

  据报道，使用生物废物咖啡因碳负载的多相钴催化剂合成了各种取代的吡咯衍生物。在该方法中，通过硝基芳烃和烯基二醇以串联方式偶联合成吡咯。在所有多相催化剂中，Co(OAc) 2 -CC-800 表现出最高的催化活性。吡咯的制备规模合成和抗结核剂 5-(4-(1H-pyrrol-1-yl)phenyl)-1,3,4-oxadiazole-2-thiol 的合成揭示了该协议的实际适用性。进行了几次动力学实验和哈米特研究，以了解这种转变的可能机制和电子效应。
• Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
  申请人：American Home Products Corporation

  公开号：US20010039348A1

  公开（公告）日：2001-11-08

  Compounds having the formula: 1 wherein R 1 -R 5 are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, —CN, —NO 2 , —CO 2 R 6 , —COR 6 , —OR 6 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CONR 7 R 8 , —NR 6 N(R 7 R 8 ), —N(R 7 R 8 ) or W-Y-(CH 2 ) n -Z provided that at least one of R 1 -R 5 is not hydrogen; or R 1 and R 2 or R 3 and R 4 , taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R 6 and R 7 are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R 8 is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R 7 and R 8 , taken together may form a 3 to 7 membered heterocycloalkyl; W is O, NR 6 , or is absent; Y is —(CO)— or —(CO 2 )—, or is absent; Z is alkyl of 1 to 4 carbon atoms, —CN, —CO 2 R 6 , COR 6 , —CONR 7 R 8 , —OCOR 6 , —NR 6 COR 7 , —OCONR 6 , —OR 6 , —SR 6 , —SOR 6 , —SO 2 R 6 , SR6N(R7R8), —N(R 7 R 8 ) or phenyl; G is aryl or fused bicyclic heteroaryl; X is a bond, —NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is an integer from 1 to 6; useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.

  化合物的化学式为1，其中R1-R5独立选择自氢、1到6个碳原子的烷基、2到6个碳原子的烯基、2到6个碳原子的炔基、1到6个碳原子的全卤烷基、3到10个碳原子的环烷基、3到10个碳成员的杂环烷基、芳基、杂芳基、卤素、-CN、-NO2、-CO2R6、-COR6、-OR6、-SR6、-SOR6、-SO2R6、-CONR7R8、-NR6N（R7R8）、-N（R7R8）或W-Y-（CH2）n-Z，其中至少一个R1-R5不是氢；或R1和R2或R3和R4，一起形成3到7个成员的杂环烷基或3到7个成员的杂芳基；R6和R7独立地为氢、1到6个碳原子的烷基、1到6个碳原子的全卤烷基或芳基；R8为氢、1到6个碳原子的烷基、1到6个碳原子的全卤烷基、3到10个碳原子的环烷基、3到10个成员的杂环烷基、芳基或杂芳基，或R7和R8一起形成3到7个成员的杂环烷基；W为O、NR6或不存在；Y为-CO-或-CO2-，或不存在；Z为1到4个碳原子的烷基、-CN、-CO2R6、COR6、-CONR7R8、-OCOR6、-NR6COR7、-OCONR6、-OR6、-SR6、-SOR6、-SO2R6、SR6N（R7R8）、-N（R7R8）或苯基；G为芳基或融合的双环杂芳基；X为键、-NH、1到6个碳原子的烷基、1到6个碳原子的烯基、1到6个碳原子的烷氧基、1到6个碳原子的硫代烷基、1到6个碳原子的烷基氨基或（CH）J；J为1到6个碳原子的烷基、3到7个碳原子的环烷基、苯基或苄基；n为1到6的整数。该化合物可用于治疗与疱疹病毒相关的疾病，包括人类巨细胞病毒、单纯疱疹病毒、EB病毒、水痘-带状疱疹病毒、人类疱疹病毒-6和-7以及卡波西疱疹病毒。